STOCKHOLM, Sweden, Nov. 09, 2005 (PRIMEZONE) -- Artimplant: CEO Tord Lendau and VP, Medical Affairs Elisabeth Liljensten presents the Interim Report for the period January -- September 2005.
The presentation will be in English
Date: Thursday, November 10 Time: 10.00 a .m. CET
Dial in Number: +44 (0)20 7365 1839
A live broadcast of the telephone conference will available on Artimplant's website www.artimplant.com
Web site: www.artimplant.com
Artimplant has also posted the following press releases the last four months on www.artimplant.com
Artimplant and ArthroCare Corporation sign distribution agreement for North America Artelon(R) nanofibers successfully used as coating on metal implants Artimplant signs four new development and license agreements with Small Bone Innovations Artimplant receives CE-mark for Artelon(R) Surgical Suture Artimplant expands its long-term degradable Artelon(R) Surgical Suture product range New study shows that Artelon(R) works as a dermal filler Artimplant expand the field of application for Artelon(R) Artimplant employs Ms. Susanne Hamilton as Product Manager Odontology Artimplant appoints Lars-Johan Cederbrant as Chief financial Officer Electrospinning of Artelon(R) in collaboration with IFP Research and Chalmers University of Technology expand the opportunities for Artimplant Artimplant boosts its commercial base through CE-mark for two new products within odontology and craniomaxillofacial surgery
About Artimplant
Artimplant is a biomaterials company focused on solutions to problems in orthopedic, odontological and reconstructive surgery. The Company is engaged in the development, production and marketing of degradable implants designed to restore active lifestyles and improve quality of life. The proprietary technology Artelon(R), a long-term degradable biomaterial, offers new solutions to unmet clinical needs and opens new markets. Artimplant's business model is that of licensing its products and technology to global partners. The Company currently has six licensing agreements with two global partners. Artimplant is a public company, listed on the Stockholm Stock Exchange, O-list.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://wpy.waymaker.net/client/waymaker1/WOLReleaseFile.aspx?id=149811&fn=wkr0001.pdf